The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

US Psych Congress Elevate
May 28th – 31st 2025, Las Vegas, NV
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Schizophrenia
ENCORE POSTER
Baseline Severity of Illness and Response to Treatment With Aripiprazole Lauroxil Every 2 Months: A Post Hoc Analysis of Phase 3 ALPINE Clinical Trial Data
AUTHOR(S)

John M. Kane, MD1; Martin Dunbar, PhD2; and James A. McGrory, PhD2

Embargo date: 05-30-2025 Embargo time: 19:05 PDT
Schizophrenia
Schizophrenia
ENCORE POSTER
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia
AUTHOR(S)

Andrew J. Cutler, MD,1,2 Hemangi R. Panchmatia, MSc,3 Alejandro G. Hughes, MPH,4 Michael J. Doane, PhD,3 Hara E. Oyedeji, CRNP, MS,5 Rakesh Jain, MD, MPH6

Embargo date: 05-30-2025 Embargo time: 19:05 PDT
Schizophrenia
Bipolar Disorder
Schizophrenia
ENCORE POSTER
Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon, MD, MPH,1 Christina Arevalo, MS,2 Martin Dunbar, PhD,2 Alexandra Lovett, MD,2 David McDonnell, MD,3 Christoph U. Correll, MD4-7

Embargo date: 05-30-2025 Embargo time: 19:05 PDT
Bipolar Disorder
Schizophrenia
Bipolar Disorder
ENCORE POSTER
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Bipolar I Disorder
AUTHOR(S)

Rakesh Jain, MD, MPH,1 Hemangi R. Panchmatia, MSc,2 Alejandro G. Hughes, MPH,3 Michael J. Doane, PhD,2 Hara E. Oyedeji, CRNP, MS,4 Andrew J. Cutler, MD5,6

Embargo date: 05-30-2025 Embargo time: 19:05 PDT
Bipolar Disorder